RP101 Phase II clinical results
March 12, 2020 8:13 amRP101 demonstrates efficacy and safety in Phase II study of patients with moderate-to-severe dry eye disease RP101 more than doubles... View Article
RP101 demonstrates efficacy and safety in Phase II study of patients with moderate-to-severe dry eye disease RP101 more than doubles... View Article
Redwood Pharma will present on March 24 in Paris, France, at BIO-Europe Spring, one of Europe’s largest life science partnership... View Article
SPOTLIGHT STOCK MARKET: REDW REDWOODPHARMA.COM 1 January – 31 December 2019 Net revenue for the period was SEK... View Article
The China National Intellectual Property Administration (CNIPA) has communicated its intention to grant a new patent in China in the... View Article
CEO Martin Vidaeus of Redwood Pharma updates industry and shareholders of the status of the RP101 Phase II trial... View Article
Redwood Pharma will be arranging RP101 partnering meetings during the upcoming JPMorgan Healthcare Conference between Jan. 13 and Jan. 15,... View Article
REDWOOD PHARMA AB (PUBL) Spotlight Stock Market: REDW redwoodpharma.com Read the quarterly report 1 January – 30 September 2019... View Article
On December 3, CEO Martin Vidaeus from Redwood Pharma will present at BioStock Live (www.biostock.se) in Stockholm. The presentation will... View Article
Redwood Pharma can today report that the last patient received their last dose in the company’s Phase II trial of... View Article
Redwood Pharma will be attending BIO-Europe, Europe’s largest life sciences partnering conference, November 10-12 in Hamburg, Germany, to discuss potential... View Article